Table 3.

Univariable analysis of subgroup of patients with active solid malignancy and COVID-19. Risk (expressed in odds ratio) of a fatal outcome of COVID-19 for the different patients’ characteristics in patients considered as having an active malignancy (n = 471).

	Patients with active malignancy (n = 471)
	Frequency n (%)	Odds ratio (95% CI)	p-value
Sex (male)	222 (47.1)	1.63 (1.06–2.51)	0.027
Age
<65 years	213 (45.2)	–	–
≥65 years < 75 years	133 (28.2)	4.55 (2.50–8.27)	<0.001
≥75 years	125 (26.5)	6.37 (3.52–11.52)	<0.001
Smoking	230 (48.8)	1.73 (1.12–2.67)	0.014
Comorbidities
Cardiovascular disease	225 (47.8)	2.60 (1.66–4.08)	<0.001
BMIa ≥ 30	102 (21.7)	0.84 (0.49–1.44)	0.525
COPDb	52 (11.0)	2.24 (1.20–4.20)	0.010
Diabetes mellitus	88 (18.7)	1.65 (0.99–2.76)	0.055
Autoimmune disease	27 (5.7)	1.19 (0.49–2.89)	0.703
Prior/other malignancy	79 (16.8)	2.30 (1.37–3.86)	0.001
Cancer type
Other solid tumours	381 (80.9)	–	–
Lung cancer	90 (19.1)	2.21 (1.34–3.65)	0.002
Last cancer treatment
Surgery	51 (10.8)	0.80 (0.39–1.66)	0.550
Radiotherapy	87 (18.5)	0.59 (0.32–1.1)	0.093
Thoracic radiotherapy	48 (10.2)	1.14 (0.57–2.27)	0.719
Chemotherapy	212 (45.0)	0.84 (0.54–1.30)	0.426
Immunotherapy	79 (16.8)	0.68 (0.37–1.27)	0.227
Targeted therapy	74 (15.7)	0.42 (0.20–0.87)	0.016
Hormonal therapy	86 (18.3)	1.11 (0.64–1.91)	0.716
Disease stage for solid tumours
Metastatic	288 (61.1)	1.89 (1.18–3.03)	0.007
Intention most recent cancer treatment given
Non-curative	292 (62.0)	1.94 (1.19–3.15)	0.007

CI, confidence interval; COVID-19, coronavirus disease 2019.

^aBMI, body mass index.

^bCOPD, chronic obstructive pulmonary disease 2.